We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

228 hedge funds and large institutions have $5.13B invested in Loxo Oncology, Inc in 2018 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 93 increasing their positions, 68 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 24

71% more call options, than puts

Call options by funds: $36.8M | Put options by funds: $21.6M

37% more repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 68

7% more funds holding

Funds holding: 213228 (+15)

0% more capital invested

Capital invested by funds: $5.11B → $5.13B (+$19.3M)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

Holders
228
Holders Change
+15
Holders Change %
+7.04%
% of All Funds
5.21%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.14%
New
41
Increased
93
Reduced
68
Closed
24
Calls
$36.8M
Puts
$21.6M
Net Calls
+$15.2M
Net Calls Change
-$2.31M
Name Holding Trade Value Shares
Change
Change in
Stake
QI
101
QS Investors
New York
$3.02M +$2.83M +16,850 +2,091%
Manulife (Manufacturers Life Insurance)
102
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2.98M -$367K -2,183 -11%
ACM
103
Atika Capital Management
New York
$2.9M -$504K -3,000 -15%
ProShare Advisors
104
ProShare Advisors
Maryland
$2.85M +$95.1K +566 +4%
AI
105
Axiom Investors
Connecticut
$2.74M -$1.08M -6,417 -29%
Principal Financial Group
106
Principal Financial Group
Iowa
$2.63M +$1.18M +7,009 +84%
AIM
107
Assured Investment Management
New York
$2.61M -$1.57M -9,360 -38%
SGH
108
Sivik Global Healthcare
Connecticut
$2.56M -$840K -5,000 -25%
Creative Planning
109
Creative Planning
Kansas
$2.49M +$888K +5,286 +57%
CIA
110
Capital Impact Advisors
Massachusetts
$2.48M +$308K +1,835 +15%
PI
111
Putnam Investments
Massachusetts
$2.47M +$252K +1,497 +12%
1832 Asset Management
112
1832 Asset Management
Ontario, Canada
$2.44M +$235K +1,400 +11%
EI
113
EAM Investors
California
$2.32M -$556K -3,310 -20%
DekaBank Deutsche Girozentrale
114
DekaBank Deutsche Girozentrale
Germany
$2.3M -$60.5K -360 -3%
EAMA
115
EFG Asset Management (Americas)
Florida
$2.29M +$885K +5,264 +65%
SEI Investments
116
SEI Investments
Pennsylvania
$2.28M -$495K -2,944 -18%
State Board of Administration of Florida Retirement System
117
State Board of Administration of Florida Retirement System
Florida
$2.15M
LCG
118
Lisanti Capital Growth
New York
$2.14M +$700K +4,165 +50%
CEP
119
Chicago Equity Partners
Illinois
$2.11M -$759K -4,515 -27%
CIP
120
Chartwell Investment Partners
Pennsylvania
$2.08M +$2.05M +12,196 New
MIM
121
MetLife Investment Management
New Jersey
$2.07M
Bank of Montreal
122
Bank of Montreal
Ontario, Canada
$1.94M +$537K +3,198 +39%
SO
123
STRS Ohio
Ohio
$1.84M +$118K +700 +7%
Fiera Capital (Canada)
124
Fiera Capital (Canada)
Quebec, Canada
$1.79M -$1.09M -6,464 -38%
PA
125
Profund Advisors
Maryland
$1.76M +$1.74M +10,333 New

LOXO Hedge Fund Activity: Q3 2018 in Review

228 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q3 2018, worth a combined $5.13B — up 0.38% from $5.11B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new LOXO positions and 24 closed out — a net gain of 17 holders — while 93 added to existing stakes and 68 trimmed.

The largest buyer was Eagle Asset Management, adding an estimated $48.9M. The largest seller was Aisling Capital, cutting an estimated $235M.

  • 228 institutional investors held Loxo Oncology, Inc (LOXO) as of Q3 2018, up from 213 in Q2 2018.
  • Funds reported $5.13B of Loxo Oncology, Inc stock for Q3 2018, up 0.38% quarter-over-quarter.
  • 41 funds opened new Loxo Oncology, Inc positions in Q3 2018 and 24 closed out, a net change of +17 holders.
  • The largest Loxo Oncology, Inc buyer in Q3 2018 was Eagle Asset Management, an estimated $48.9M added.
  • The largest Loxo Oncology, Inc seller in Q3 2018 was Aisling Capital, an estimated $235M sold.

Based on aggregated 13F filings for Q3 2018.